featured
2015 Top Stories in Advanced Prostate Cancer: ECOG CHAARTED Trial
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
- Sweeney C, Chen Y, Carducci M. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. N Engl J Med 2015;373(8):737-746.
- MR, Mason MD, et al. Docetaxel and/or zoledronic acid for hormone-naïve prostate cancer: First overall survival results from STAMPEDE (NCT00268476). Paper presented at 51st Annual Meeting of the American Society of Clinical Oncology; May 29-June 2, 2015; Chicago, IL. Abstract 5001.
- Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004;351(15):1502-1512.
- Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med. 2004;351(15):1513-1520.
Disclosure statements are available on the authors' profiles: